Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.